Bayer in $1.3 bn deal for cancer drug candidate
<img width="1024" height="678" src="https://insiderpaper.com/wp-content/uploads/2023/01/cancer-g5bf97caec_1280-1024x678.jpg"/>German pharmaceutical giant Bayer said Tuesday it had struck a deal valued at up to $1.3 billion (1.1 billion euros) with a US-based biotech company to develop its prospective cancer drug. Under the agreement, Kumquat Biosciences is responsible for initiating and completing a study into the medicine while Bayer will complete development and commercial activities. […]
The post
.


Insider Paper
Bayer in $1.3 bn deal for cancer drug candidate
German pharmaceutical giant Bayer said Tuesday it had struck a deal valued at up to $1.3 billion (1.1 billion euros) with a US-based biotech compan...

Insider Paper
Bayer in $1.3 bn deal for cancer drug candidate
German pharmaceutical giant Bayer said Tuesday it had struck a deal valued at up to $1.3 billion (1.1 billion euros) with a US-based biotech compan...




